Amicus Therapeutics Appoints Jay A. Barth, MD as Chief Medical Officer and Promotes Bradley L. Campbell to Chief Operating

Amicus Therapeutics Appoints Jay A. Barth, MD as Chief Medical Officer and
Promotes Bradley L. Campbell to Chief Operating Officer

CRANBURY, N.J., March 3, 2014 (GLOBE NEWSWIRE) -- Amicus Therapeutics
(Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for
rare and orphan diseases, today announced the appointment of Jay A. Barth, MD
as Chief Medical Officer, effective today. Dr. Barth brings to Amicus more
than 15 years of experience in drug development, clinical research and medical
affairs. In his role as Chief Medical Officer, he will be responsible for all
clinical development activities as well as regulatory affairs. The Company
also announced the promotion of Bradley L. Campbell from Chief Business
Officer to Chief Operating Officer, effective December 2013. Both Dr. Barth
and Mr. Campbell report to John F. Crowley, Chairman and Chief Executive
Officer of Amicus.

Mr. Crowley stated, "I am thrilled to welcome Dr. Jay Barth to our team at
Amicus. Jay is the ideal person to lead our clinical and regulatory teams in
the execution of our 3-in-3 strategy to advance three next-generation ERTs
into the clinic over the next three years. His direct experience in clinical
development, medical affairs and regulatory strategy within the rare diseases
will be extremely valuable to Amicus. I would also like to congratulate
Bradley Campbell on his promotion to Chief Operating Officer, as he assumes a
leadership role in research and development while continuing to lead several
other important Amicus teams including program management, business
development, technical operations and patient advocacy. Brad will continue to
be a key leader at Amicus."

Prior joining Amicus, Dr. Barth held roles of increasing responsibility at PTC
Therapeutics, Inc. from 2009 to 2014. He most recently served as PTC's Senior
Vice President, Clinical Development. In this role he led the clinical team
and oversaw all global clinical development programs, focusing on rare
diseases including Duchenne Muscular Dystrophy and Cystic Fibrosis. He also
worked with PTC's regulatory affairs team to develop U.S. and European
regulatory strategy, communicate with regulatory agencies, and prepare
marketing applications for submission. Previously Dr. Barth served as
Executive Director of Clinical Research at Merck; as Vice President, Clinical
Research and Medical Affairs at Altana Pharma US, Inc; and as Senior Director,
Global Head of Gastroenterology Clinical Research at Eisai Medical Research
Inc.

Dr. Barth received a B.A. from Columbia University and an M.D. from the
University of Pennsylvania School of Medicine. He is a member of the American
Gastroenterological Association, the American College of Gastroenterology, and
the North American Society for Pediatric Gastroenterology, Hepatology, and
Nutrition. He is also the author of numerous publications in the fields of
medicine and clinical research.

Mr. Campbell has over a decade of experience in the rare and orphan disease
field at both Amicus and Genzyme. He joined Amicus in 2006 and has assumed
positions of increasing responsibility, most recently serving as Chief
Business Officer. In his new role, Mr. Campbell will remain the head of
several departments including Business Development, Program Management,
Commercial Planning, Patient and Professional Advocacy, and Technical
Operations, with increased responsibility in overseeing preclinical research
and development. Mr. Campbell received his B.A. in Public Policy from Duke
University and his M.B.A. from Harvard Business School.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the
forefront of therapies for rare and orphan diseases. The Company is developing
novel, first-in-class treatments for a broad range of human genetic diseases,
with a focus on delivering new benefits to individuals with lysosomal storage
diseases. Amicus' lead programs include the small molecule pharmacological
chaperones migalastat HCl as a monotherapy and in combination with enzyme
replacement therapy (ERT) for Fabry disease; and AT2220 (duvoglustat HCl) in
combination with ERT for Pompe disease.

Forward-Looking Statements

This press release contains, and the accompanying conference call will
contain, "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995 relating to preclinical and clinical
development of Amicus' candidate drug products, the timing and reporting of
results from preclinical studies and clinical trials evaluating Amicus'
candidate drug products and the projected cash position for the Company. Words
such as, but not limited to, "look forward to," "believe," "expect,"
"anticipate," "estimate," "intend," "potential," "plan," "targets," "likely,"
"may," "will," "would," "should" and "could," and similar expressions or words
identify forward-looking statements. Such forward-looking statements are based
upon current expectations that involve risks, changes in circumstances,
assumptions and uncertainties. The inclusion of forward-looking statements
should not be regarded as a representation by Amicus that any of its plans
will be achieved. Any or all of the forward-looking statements in this press
release may turn out to be wrong. They can be affected by inaccurate
assumptions Amicus might make or by known or unknown risks and uncertainties.
For example, with respect to statements regarding the goals, progress, timing
and outcomes of discussions with regulatory authorities and the potential
goals, progress, timing and results of preclinical studies and clinical
trials, actual results may differ materially from those set forth in this
release due to the risks and uncertainties inherent in the business of Amicus,
including, without limitation: the potential that results of clinical or
pre-clinical studies indicate that the product candidates are unsafe or
ineffective; the potential that it may be difficult to enroll patients in our
clinical trials; the potential that regulatory authorities may not grant or
may delay approval for our product candidates; the potential that preclinical
and clinical studies could be delayed because we identify serious side effects
or other safety issues; the potential that we will need additional funding to
complete all of our studies and, our dependence on third parties in the
conduct of our clinical studies. Further, the results of earlier preclinical
studies and/or clinical trials may not be predictive of future results. With
respect to statements regarding projections of the Company's cash position,
actual results may differ based on market factors and the Company's ability to
execute its operational and budget plans. In addition, all forward looking
statements are subject to other risks detailed in our Annual Report on Form
10-K for the year ended December 31, 2012. You are cautioned not to place
undue reliance on these forward-looking statements, which speak only as of the
date hereof. All forward-looking statements are qualified in their entirety by
this cautionary statement, and Amicus undertakes no obligation to revise or
update this news release to reflect events or circumstances after the date
hereof. This caution is made under the safe harbor provisions of Section 21E
of the Private Securities Litigation Reform Act of 1995.

FOLD–G

CONTACT: Investors/Media:
         Sara Pellegrino
         spellegrino@amicusrx.com
         (609) 662-5044
        
         Media:
         Dan Budwick
         dan@purecommunicationsinc.com
         (973) 271-6085
 
Press spacebar to pause and continue. Press esc to stop.